A clinical trial is underway to evaluate the safety and dosing of JNJ-88549968 for CALR-mutated myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis.

Upcoming catalysts

No catalysts indexed for this entity yet.

Regulatory activity

No signals indexed for this entity yet.

Clinical activity(1)

ClinicalAugust 12, 2026

Phase 1/2 Study of JNJ-88549968 in CALR-Mutated Myeloproliferative Neoplasms

A clinical trial is underway to evaluate the safety and dosing of JNJ-88549968 for CALR-mutated myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis.

Competitive activity

No signals indexed for this entity yet.

Assets

ruxolitinib →

Therapeutic areas

Hematology →

Myeloproliferative Neoplasms →

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.